Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TSHA
- Price
- 1.17
- Stock movement down
- -0.03 (-2.50%)
- Company name
- Taysha Gene Therapies Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 239.78M
- Ent value
- 173.52M
- Price/Sales
- 24.18
- Price/Book
- 2.70
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -60.47%
- 3 year return
- -44.02%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TSHA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 24.18 |
| Price to Book | 2.70 |
| EV to Sales | 17.50 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 204.94M |
| EPS (TTM) | -0.09 |
| FCF per share (TTM) | -0.30 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.91M |
| Gross profit (TTM) | 8.92M |
| Operating income (TTM) | -87.32M |
| Net income (TTM) | -22.77M |
| EPS (TTM) | -0.09 |
| EPS (1y forward) | -0.26 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 90.00% |
| Operating margin (TTM) | -880.73% |
| Profit margin (TTM) | -229.67% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 157.69M |
| Net receivables | 0.00 |
| Total current assets | 161.56M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 180.22M |
| Accounts payable | 4.93M |
| Short/Current long term debt | 62.54M |
| Total current liabilities | 29.34M |
| Total liabilities | 91.42M |
| Shareholder's equity | 88.80M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -79.05M |
| Capital expenditures (TTM) | 393.00K |
| Free cash flow (TTM) | -79.44M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -25.64% |
| Return on Assets | -12.64% |
| Return on Invested Capital | -25.13% |
| Cash Return on Invested Capital | -87.68% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.19 |
| Daily high | 1.22 |
| Daily low | 1.08 |
| Daily Volume | 1.01M |
| All-time high | 31.75 |
| 1y analyst estimate | 6.59 |
| Beta | 0.41 |
| EPS (TTM) | -0.09 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 29 May 2025 |
Downside potential
Loading...
Downside potential data
| TSHA | S&P500 | |
| Current price drop from All-time high | -96.31% | -14.41% |
| Highest price drop | -98.14% | -56.47% |
| Date of highest drop | 28 Jun 2023 | 9 Mar 2009 |
| Avg drop from high | -74.24% | -11.07% |
| Avg time to new high | 190 days | 12 days |
| Max time to new high | 1062 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
239.78M
Marketcap category
Small-cap
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Employees
52
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page